PHILADELPHIA, July 14, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that all outstanding legal issues between Hemispherx and Bioclones (Proprietary), Ltd. and Ribotech (Pty) Ltd have been resolved and that all litigation between the companies is in the process of being dismissed by mutual agreement. Additionally, based on current discussions, Hemispherx management sees the potential for a mutually beneficial new Ampligen(r) partnership with the principals now controlling Bioclones and Ribotech.
